TMTPOST — Percutaneous ventricular assist device developer Enginprime Medical has completed a Series A financing of nearly RMB 100 million, the company announced on Monday. Qiming Venture Partners provided the exclusive investment. Proceeds will accelerate the domestic registration clinical trial of the company’s lead product, OpusOne™, and support regulatory filings and early-stage clinical development of the platform overseas. Founded in 2023 and incubated by Voyagers Capital, Enginprime focuses on next-generation percutaneous ventricular assist systems that deliver higher flow rates from a smaller catheter profile through a foldable impeller design. The device aims to reduce complications and expand treatment options for patients requiring temporary circulatory support during high-risk cardiac procedures.